# Athenex, Inc. clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Athenex, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Athenex, Inc.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/athenex-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 4, 2022 | NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies | Athenex, Inc. | Phase 1 | Unknown | NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05487651) |
| August 6, 2021 | NCT04993040 | A PK Study of Oraxol in Breast Cancer Patients | Athenex, Inc. | Phase 1 | Completed | Breastcancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04993040) |
| May 7, 2021 | NCT04878484 | Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors | Athenex, Inc. | Phase 1 | Withdrawn | Advanced Solid Tumor | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04878484) |
| November 27, 2019 | NCT04180384 | A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients | Athenex, Inc. | Phase 2 | Completed | Solid Tumor | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04180384) |
| November 19, 2019 | NCT04168957 | An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007 | Athenex, Inc. | Phase 1 | Terminated | Breastcancer | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04168957) |
| October 23, 2019 | NCT04136834 | A Phase I Open-label Study for Subjects With Advanced Malignancies | Athenex, Inc. | Phase 1 | Unknown | Advanced Solid Malignancies | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04136834) |
| July 29, 2019 | NCT04035473 | A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel | Athenex, Inc. | Phase 1 | Completed | Solid Tumor | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04035473) |
| June 17, 2019 | NCT03987685 | Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies | Athenex, Inc. | Phase 1 | Completed | Solid Tumor | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03987685) |
| March 27, 2019 | NCT03892018 | The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol | Athenex, Inc. | Phase 1 | Terminated | Solid Tumor, Adult | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03892018) |
| July 17, 2018 | NCT03588039 | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | Athenex, Inc. | Phase 1 | Terminated | Solid Tumor | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03588039) |
| July 3, 2018 | NCT03575780 | Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic... | Athenex, Inc. | Phase 1 | Completed | Actinic Keratoses | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03575780) |
| June 4, 2018 | NCT03544567 | A Study of Oraxol in Subjects With Cutaneous Angiosarcoma | Athenex, Inc. | Phase 2 | Completed | Angiosarcoma of Skin | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03544567) |
| November 22, 2016 | NCT02970539 | Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers | Athenex, Inc. | Phase 1 | Unknown | Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02970539) |
| November 15, 2016 | NCT02963168 | A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies | Athenex, Inc. | Phase 1 | Unknown | Solid Tumor | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02963168) |
| April 6, 2016 | NCT02730481 | A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies | Athenex, Inc. | Phase 1 | Completed | Solid Tumor | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02730481) |
| November 3, 2015 | NCT02594371 | Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer | Athenex, Inc. | Phase 3 | Completed | Metastatic Breast Cancer | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02594371) |
| January 13, 2015 | NCT02337205 | Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis | Athenex, Inc. | Phase 1 | Completed | Actinic Keratosis | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02337205) |
| December 29, 2014 | NCT02326441 | Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies | Athenex, Inc. | Phase 1 | Completed | Advance Malignancies | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02326441) |
| September 26, 2014 | NCT02250157 | A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced... | Athenex, Inc. | Phase 1 | Completed | Solid Tumor | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02250157) |
| February 24, 2010 | NCT01074138 | Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer | Athenex, Inc. | Phase 2 | Completed | Bone-Metastatic, Castration-Resistant Prostate Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01074138) |
| April 16, 2008 | NCT00658970 | Evaluation of KX2-391 in Patients With Advanced Malignancies | Athenex, Inc. | Phase 1 | Completed | Solid Tumors, Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00658970) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 2 | 3 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Unknown | 4 |
| Terminated | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 2 |
| Keratosis, Actinic | 2 |
| Lymphoma | 1 |
| Stomach Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Recurrence | 1 |
| Lymphoma, B-Cell | 1 |
| Leukemia, B-Cell | 1 |
| Dendritic Cell Sarcoma, Interdigitating | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Tractor dealers in the United States](https://specstream.ai/data/businesses/tractor-dealers/united-states)
- [Commercial real estate firms in the United States](https://specstream.ai/data/businesses/commercial-real-estate-firms/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Sports bars in the United States](https://specstream.ai/data/businesses/sports-bars/united-states)
- [Cafes in the United States](https://specstream.ai/data/businesses/cafes/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
